Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Blood (2023) 142 (Supplement 1): 4437.

https://doi.org/10.1182/blood-2023-188449

Published: 2023

Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Blood (2023) 142 (Supplement 1): 160.

https://doi.org/10.1182/blood-2023-184445

Published: 2023

Journal Articles

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Blood (2022) 140 (Supplement 1): 523–525.

https://doi.org/10.1182/blood-2022-157126

Published: 2022

Journal Articles

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients - a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)

Blood (2022) 140 (Supplement 1): 1773–1774.

https://doi.org/10.1182/blood-2022-162157

Published: 2022

Journal Articles

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Sonia Jaramillo Segura, Maxi Wass, Judith Schaffrath, Kathrin Rieger, Axel Nogai, Mathias Haenel, Regina Herbst, Friedrich Stoelzel, Christoph Röllig, Edgar Jost, Richard F. Schlenk, Richard Noppeney, Christian H. Brandts, Utz Krug, Katharina S. Goetze, Sebastian Buske, Axel Florschütz, Jörg Schubert, Bernhard Opitz, Martin Mohren, Eva Eßeling, Stephan von Witzendorff, Marion Subklewe, Martin Kaufmann, Norbert Frickhofen, Christian W Scholz, Kerstin Schäfer-Eckart, Volker Kunzmann, Martin Schmidt-Hieber, Herbert G. Sayer, Andreas Rank, Philipp Hemmati, Frank Schueler, Simone Kowoll, Marina Scheller, Jörg Steighardt, Bayram Edemir, Lutz Peter Mueller, Irit Gliko-Kabir, Beatrice Ludwig-Kraus, Sabine Edemir, Ella Sorani, Mascha Binder, Abi Vainstein, Shaul Kadosh, Cora Gromann, Andreas Wienke, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhaeuser, Christian Junghanss, Carsten Mueller-Tidow

Blood (2022) 140 (Supplement 1): 3338–3340.

https://doi.org/10.1182/blood-2022-166748

Published: 2022

Journal Articles

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Blood (2022) 140 (Supplement 1): 510–512.

https://doi.org/10.1182/blood-2022-162235

Published: 2022

Journal Articles

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Blood (2021) 138 (Supplement 1): 2300.

https://doi.org/10.1182/blood-2021-145553

Published: 2021

Journal Articles

Fast-Track Schedule for Vitamin D3 Substitution in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Jonas Matthias Jabs, Viola Poeschel, MD, Martin Sökler, MD, Kerstin Habersang, MD, Rolf Mahlberg, MD, Ulrich Keller, Professor Dr, Heinz-Gert Hoeffkes, Professor Dr, Andreas Rank, PD Dr, Andreas Viardot, Professor Dr, Andreas Neubauer, Professor Dr, Marita Ziepert, PhD, Bettina Altmann, PhD, Stephan Stilgenbauer, MD, Michael Pfreundschuh, Professor Dr, Gerhard Held, Professor Dr, Joerg Thomas Bittenbring, MD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-134944

Published: 2020

Journal Articles

First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial)

Matthias Stelljes, MD, Simon Raffel, MD, Ralph Wäsch, Sebastian Scholl, Mustafa Kondakci, MD, Andreas Rank, PD Dr, Mathias Haenel, MD, Sonja Martin, MD, Katjana Schwab, MD, Julian Knaden, Klaus Wethmar, MD, Tim Sauer, MD, Wolfgang E. Berdel, Prof., MD, Georg Lenz, Martin Dugas, Monika Brüggemann, MD, Nicola Goekbuget, MD, Nael Alakel, MD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-136920

Published: 2020

Journal Articles

Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-140246

Published: 2020

Journal Articles

The Multicentre, Double-Blinded, Placebo-Controlled Clinical-Trial (Pre-GvHD) for Prediction and Pre-Emptive Treatment of Acute GvHD

Blood (2017) 130 (Supplement 1): 512.

https://doi.org/10.1182/blood.V130.Suppl_1.512.512

Published: 2017

Journal Articles

A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Bastian von Tresckow, MD, Annette Pluetschow, Heinz Haverkamp, Vladan Vucinic, MD, Andreas Rank, MD, Max S. Topp, MD, Michaela Feuring-Buske, MD, Carsten Kobe, MD, Georg Kuhnert, MD, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Michael Fuchs, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2014) 124 (21): 4433.

https://doi.org/10.1182/blood.V124.21.4433.4433

Published: 2014

Journal Articles

Bone Marrow Contains High Levels of Microparticles

Andreas Rank, MD, Rienk Nieuwland, PhD, Anton Koehler, MD, Hans Jochem Kolb, MD, Bettina Toth, MD

Blood (2014) 124 (21): 5145.

https://doi.org/10.1182/blood.V124.21.5145.5145

Published: 2014

Journal Articles

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

Blood (2012) 119 (6): 1599–1606.

https://doi.org/10.1182/blood-2011-08-375840

Published: 2012

Includes: Supplemental data

Journal Articles

Does Microangiopathy Predict Chronic GvHD After Allogeneic Stem Cell Transplantation? A Clinical and Immunohistochemical Study on Bone Marrow Biopsies

Wolfgang Hill, MD, Karl Sotlar, MD, Hans Jochem Kolb, MD, Andreas Hausmann, MD, Johanna Tischer, MD, Andreas Rank, MD

Blood (2011) 118 (21): 4540.

https://doi.org/10.1182/blood.V118.21.4540.4540

Published: 2011

Journal Articles

Allogeneic Stem Cell Transplantation for MDS and sAML Following Reduced Intensity Conditioning and Preemptive Donor Lymphocyte Transfusion.

Hans-Jochem Kolb, MD, PhD, Christoph Schmid, MD, Johanna Tischer, MD, Andreas Haussmann, MD, Andreas Rank, MD, Michael Schleuning, MD, Georg Ledderose, MD

Blood (2006) 108 (11): 324.

https://doi.org/10.1182/blood.V108.11.324.324

Published: 2006

Journal Articles

Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation

Thorsten Kaiser, Haytham Kamal, Andreas Rank, Hans-Jochem Kolb, Ernst Holler, Arnold Ganser, Bernd Hertenstein, Harald Mischak, Eva Maria Weissinger

Blood (2004) 104 (2): 340–349.

https://doi.org/10.1182/blood-2004-02-0518

Published: 2004

NARROW

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients - a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Fast-Track Schedule for Vitamin D3 Substitution in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial)

Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

The Multicentre, Double-Blinded, Placebo-Controlled Clinical-Trial (Pre-GvHD) for Prediction and Pre-Emptive Treatment of Acute GvHD

A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Bone Marrow Contains High Levels of Microparticles

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

Does Microangiopathy Predict Chronic GvHD After Allogeneic Stem Cell Transplantation? A Clinical and Immunohistochemical Study on Bone Marrow Biopsies

Allogeneic Stem Cell Transplantation for MDS and sAML Following Reduced Intensity Conditioning and Preemptive Donor Lymphocyte Transfusion.

Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only